Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
RESEARCH TOOLSreports
Aldeyra Therapeutics (ALDX) Stock Price & Analysis
1,483 Followers
ALDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.42 - $11.97
Previous Close$4.25
Volume582.03K
Average Volume (3M)588.74K
Market Cap
$250.31M
Enterprise Value$265.96M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$15.66M
Price to Earnings (P/E)-6.7
Beta1.88
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding58,895,768
10 Day Avg. Volume1,159,927
30 Day Avg. Volume588,743
Standard Deviation0.26
R-Squared0.09
Alpha0.00181
Financial Highlights & Ratios
Price to Book (P/B)2.09
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)125.00
P/FCF Ratio61.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.63
Forecast
1Y Price Target
$9.50Price Target Upside123.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Aldeyra Therapeutics News
PremiumCompany Announcements
Aldeyra Therapeutics Unveils Reproxalap Development Update
PremiumPre-Earnings
Is ALDX a Buy, Before Earnings?Ownership Overview
29.77% Insiders
14.15% Mutual Funds
9.28% Other Institutional Investors
46.80% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALDX FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was $1.42 and its highest was $11.97 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Currently, no data Available
When is Aldeyra Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aldeyra Therapeutics’s earnings last quarter?
Currently, no data Available
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 58,895,767 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Among the largest hedge funds holding Aldeyra Therapeutics’s share is Perceptive Advisors LLC. It holds Aldeyra Therapeutics’s shares valued at 30M.
---
Aldeyra Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.50 (123.53% Upside)
$9.50 (123.53% Upside)
Blogger Sentiment
Bullish
ALDX Sentiment 85%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.37%
12-Months-Change
Fundamentals
Return on Equity
-27.73%
Trailing 12-Months
Asset Growth
-18.18%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
---
ALDX Stock 12 Months Forecast
Average Price Target
$9.50
▲(123.53% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Protagonist Therapeutics
―
Clearside Biomedical
―
Crispr Therapeutics AG
―
Best Analysts Covering ALDX
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+42.33%
initiated a buy rating 16 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +42.33% per trade.
---